Management ChangeApr 30, 2026, 08:00 AM
PRQR Nominates Lykke Hinsch Gylvin to Board of Directors
AI Summary
ProQR Therapeutics N.V. announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, to its Board of Directors. Dr. Hinsch Gylvin, currently Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, brings over 20 years of global leadership experience in drug development across various therapeutic areas. Her extensive expertise is expected to complement the Board and support ProQR's pipeline advancement and strategic growth. The nomination awaits shareholder approval at the company's upcoming Annual General Meeting.
Key Highlights
- ProQR Therapeutics N.V. nominated Lykke Hinsch Gylvin to its Board of Directors.
- Dr. Gylvin currently serves as Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim.
- She brings over 20 years of global leadership experience in drug development.
- Her prior roles include senior positions at Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck.
- The nomination is subject to shareholder approval at the upcoming Annual General Meeting.
- If appointed, Dr. Gylvin will serve as an independent non-executive director.
Price Impact
More from PRQR